Based on the pharmacokinetics of the pneumococcus, purified polysaccharides antigen vaccine, there are no conceivable porphyrinogenic effects.

Purified polysaccharides antigen of 23 different serotypes.

The pneumococcal vaccine is indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine in persons over the age of 2, who are at increased risk for pneumococcal disease. The vaccine can be injected subcutaneously or intramuscularly as a single dose.

The pneumococcus vaccine is not metabolized by the cytochrome P450 system.

Uneventful use reported in 1 patient with acute porphyria.